

# RAS Targeting Therapies Market, 2021-2031 By Roots Analysis

RAS Targeting Therapies Market, 2021-2031 By Roots Analysis

LONDON, ENGLAND, UNITED KINGDOM, November 1, 2021 /EINPresswire.com/ -- [Roots Analysis](#) has announced the addition of “[RAS Targeting Therapies Market, 2021-2031](#)” report to its list of offerings.

Growing research activity in the RAS targeting domain has resulted in a surge in the interest of biopharmaceutical developers in this rapidly evolving sector. These therapies are being developed against specific oncogenic RAS mutations that are believed to be responsible for close to 30% of the overall human cancers. Moreover, the first and only approved RAS targeted therapy, named LUMAKRASTM, has provided a boost to this market, by providing a treatment for a previously deemed undruggable target.

To order this 140+ page report, which features 95+ figures, please visit <https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html>

The financial opportunity associated with the RAS [targeting therapies market](#) has been analyzed across the following segments:

- ☐ Target Indication
- ☐ Acute Myeloid Leukemia
- ☐ Colorectal cancer

**Example highlights**

**List of RAS Targeting Therapies**

S. No.	Developer Name	Drug Name	Current Status	Drug Class	Type of Therapy	Target Gene	Route of Administration	Line of Treatment	Target Indication	Trial ID
1	AMGEN	LUMAKRAS™	Approved	Small Molecule	Monotherapy	KRAS	Oral	22 line of therapy	Non-Small Cell Lung Cancer	NCT04303780
8	targovax	TG01	Phase II	Peptide Cancer Vaccine						
22	Humangen	Lenzilumab	Phase II	Monoclonal Antibody						
38	moderna	mRNA-5671/V941	Phase I	Oligonucleotide						
86	Nanogen	KRAS-siRNA NP	Preclinical	Oligonucleotide						
105	Aro	ABI300	Preclinical	Oligonucleotide						
124	p3 (i.e.)	KRAS Protein Vaccine	Preclinical	Peptide Cancer Vaccine						
148	CytosBio	SQZ-AAC-KRAS	Discovery	Cell Therapy						
159	HUMAB	HBI-2376	Discovery	Small Molecule						

*Information on 85+ unique and novel therapy candidates targeting RAS (KRAS / HRAS / NRAS) gene is available in the detailed report*

Note 1: Analysis includes therapies for which information on the aforementioned parameters was available.  
Note 2: Other indications for which RAS targeting therapies are being investigated include Breast cancer, COVID-19, Glioblastoma, Multiple Myeloma, Ovarian cancer, Psoriasis-16 Dermid syndrome, Prostate cancer and Rectal cancer

2021 © Roots Analysis

---

**Example highlights**

**RAS Targeting Therapy Developers: Product Competitiveness Analysis**  
*Distribution of Developers based in North America (Peer Group 1)*

An in-depth analysis of players, developing therapies against RAS oncogene, based on various parameters across various geographies (North America, Europe and Asia-Pacific), is available in the report titled RAS Targeting Therapies Market, 2021-2031

An insightful competitiveness analysis, featuring a 2x2 matrix wherein we have presented a relative assessment of the various products that are either in the market, or under development, based on their individual specifications and the strengths of their respective brands

2021 © Roots Analysis

RAS Targeting Therapies - RootsAnalysis

- Head and Neck cancer
- Lung cancer
- Ovarian cancer
- Pancreatic cancer
- Helan-Mcdermid Syndrome
- Skin cancer

- Type of Molecule
- Biologic
- Small Molecule

- Type of Therapy
- Monotherapy
- Combination Therapy

- Route of Administration
- Intravenous
- Intradermal
- Oral

To order this 140+ page report, which features 95+ figures, please visit <https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html>

- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World

The RAS Targeting Therapies Market, 2021-2031 report features the following companies, which we identified to be key players in this domain:

- Amgen
- AstraZeneca
- BridgeBio
- Boehringer Ingelheim
- Jacobio Pharmaceuticals
- Mirati Therapeutics
- Moderna
- Novartis
- Onconova Therapeutics
- Revolution Medicine

**Example highlights**

**RAS Targeting Therapies: Market Landscape**  
Distribution by Phase of Development

**Distribution by Line of Treatment and Type of Therapy<sup>1,2</sup>**

*Insightful graphical summaries, offering diverse perspectives concerning the current product pipeline based on several relevant parameters*

**RAS Targeting Therapies: Market Landscape**  
Distribution by Route of Administration

**Executive Insight**  
Chief Executive Officer, an Israeli based organization: *Our product is a first-of-its-kind molecule in clinical development that directly targets KRAS. It is worth mentioning that none of the inhibitors have been effectively developed to silence KRAS, till date. Specifically, molecular antibodies cannot be used to target this mutation as the target is located within the cell. We further observed that targeting KRAS using RNAi is very effective and extremely potent. However, for the treatment of pancreatic cancer, we are still focused on developing therapies targeting KRAS.*

*Excerpts of conversations, featuring relevant insights on the current status and likely evolution of market, with representatives from key stakeholder companies*

© 2021 | © Roots Analysis

## RAS Targeting Therapies by Target Indication

# Roots Analysis

BUSINESS RESEARCH & CONSULTING

Roots Analysis logo

□Margovax

□Merastem Oncology

To request a sample copy / brochure of this report, please visit

<https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html>

Table of Contents

1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Clinical Trials and Endpoint Analysis
6. Product Competitiveness Analysis
7. Company Profiles
8. Publication Analysis
9. Partnerships and Collaborations
10. Funding and Investments Analysis
11. Key Commercialization Strategies
12. Market Sizing and Opportunity Analysis
13. Appendix: List of Companies and Organizations

To purchase a copy, please visit <https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html>

Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Gaurav Chaudhary

Roots Analysis

+1 415-800-3415

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/555244276>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.